Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Emeryville, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ligand Pharmaceuticals reports stellar Q4 earnings and growth prospects

Ligand Pharmaceuticals demonstrated robust financial performance in Q4 2022, driven by strong royalty revenue growth and strategic initiatives.
While facing challenges in cost optimization and label expectations, Ligand's focus on operational efficiency and growth opportunities positions it well for the future.
With a solid financial foundation, a diverse portfolio of assets, and a commitment to strategic growth, Ligand is poised for continued success and value creation.

Ligand Pharmaceuticals excels in Q1, eyes growth through strategic assets

Ligand Pharmaceuticals delivered robust Q1 results, positioning itself for continued growth and financial stability.
The company's strategic focus on high-quality assets, diversification, and efficient deal execution underscores its commitment to driving value for investors.
Despite market challenges, Ligand remains optimistic, leveraging opportunities in the biopharmaceutical sector to sustain growth and enhance shareholder value.

Ligand Pharmaceuticals excels in Q2, eyes strategic growth opportunities

Ligand Pharmaceuticals delivered a robust performance in Q2 2023, driven by strong revenue growth and strategic financial moves.
While facing challenges in contract revenue and competitive markets, Ligand's focus on key products and acquisitions signals resilience and adaptability.
Opportunities lie in expanding revenue streams, navigating market dynamics, and leveraging FDA developments for future growth.

Ligand Pharmaceuticals reports robust Q3 earnings and strategic investments

Ligand Pharmaceuticals showcased strong financial performance, strategic investments in late-stage products, and a focus on revenue growth and portfolio management. Despite challenges in clinical trials and market estimations, the company's emphasis on growth and investor engagement presents opportunities for future success.

Ligand Pharmaceuticals reports robust Q4 earnings and strategic growth moves

Ligand Pharmaceuticals showcased a strong financial performance in Q4 2023, with strategic business streamlining and portfolio enhancements driving growth. Despite supply constraints related to a predecessor product, successful collaborations have ensured manufacturing readiness for key products like Rylaze. The company's diversified portfolio and strong partnerships position it well for continued growth and shareholder returns in 2024.

Ligand Pharmaceuticals reports robust Q1 performance and strategic investments

Ligand Pharmaceuticals shows strong financial performance and growth potential, supported by strategic partnerships and key developments in their portfolio.
While facing challenges like upcoming generic competition and revenue uncertainty from recent deals, the company remains focused on long-term growth.
Opportunities lie in projected revenue and EPS growth, market expansion for Filspari, and continued interest in licensing for revenue diversification.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Michael Jeong - Investor Relations Todd Davis - Chief Executive Officer Paul Hadden - Senior Vice President, Investments & Business Development Karen Reeves - Senior Vice President-Clinical Strategy & Investments Matt Korenberg - President & Chief Operating Officer Tavo Espinoza - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Joe Pantginis - H.C. Wainwright Operator Thank you for standing by.

Ligand Pharmaceuticals Incorporated (LGND) Q1 2024 Earnings Call Transcript

Ligand Pharmaceuticals (LGND) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $2.28 per share a year ago.

Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. “We are pleased to report another quarter of strong financial results driven by the performance of our commercial royalty portfolio. Simultaneou.

Ligand Reports First Quarter 2024 Financial Results

Agenus

JUPITER, Fla. and LEXINGTON, Mass.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the companies have entered into a royalty financing agreement to support Agenus' key development initiatives in the ongoing BOT/BAL clinical development program, including its planned confirmatory Phase 3 trial in its lead indication of patients with.

Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement

Oscar Health

Penumbra

Several top-rated Zacks Medical sector stocks are standing out ahead of their quarterly reports on Tuesday, May 7.

Don't Overlook These Top Medical Stocks as Q1 Earnings Approach

BioMarin Pharmaceutical

Blueprint Medicines

Immunovant Inc

Kymera Therapeutics

New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.

5 Biotech Stocks Worth Adding to Your Portfolio in 2024

Royalty Aggregators like Royalty Pharma, Ligand, and XOMA are gaining popularity in the biotech industry. These companies buy up royalty rights to pharmaceutical products, providing upfront cash to biotech companies. This allows biotech companies to access immediate funds for research and development, while the aggregators earn a return on their investment.

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Conference Call and Webcast Information Date: Tuesday, May 7, 2024 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Conference.

Ligand to Report First Quarter 2024 Financial Results on May 7, 2024

The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know

Applied Optoelectronics

ACM Research

Couchbase

CECO Environmental Corp

VAALCO Energy

PAR Technology

It may sound counterintuitive but if you want big gains, you have to think small, as in small-cap stocks. Here, the idea is to trade predictability for maximum profit potential.

7 Small-Cap Stocks for the Thinking Speculator

LONDON--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partners at the University of Minnesota (UMN) and CURx Pharmaceuticals, Inc. presented new data on Captisol-enabled™ Topiramate Injection (IV topiramate), a potential replacement therapy for the treatment of certain emergent neurological conditions, including epilepsy, when oral administration is not feasible. The poster was featured at the 9th London-Innsbruck Colloquium on Status Epilepticus a.

Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

Ligand Pharmaceuticals (LGND) closed at $77.96 in the latest trading session, marking a -0.03% move from the prior day.

Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It?

Zacks.com users have recently been watching Ligand (LGND) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know

JUPITER, Fla. & DURHAM, N.C.--(BUSINESS WIRE)--Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer. Pelthos is committed to commercializing innovative, safe, and efficacious therapeutic products to help patients impacted by diseases with limited treatment options. The company's lead product is ZELSUVMI™ (berdazimer) t.

Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™

In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $73.60, marking a +0.68% move from the previous day.

Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note

In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $68.64, indicating a -0.88% shift from the previous trading day.

Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know

Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock

In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $73.11, indicating a +1.25% shift from the previous trading day.

Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider

Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True?

Ligand Pharmaceuticals (LGND) reachead $71.93 at the closing of the latest trading day, reflecting a -1.14% change compared to its last close.

Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors

Ligand (LGND) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is Trending Stock Ligand Pharmaceuticals Incorporated (LGND) a Buy Now?

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Thursday, March 14, 2024, at 10:45 a.m. Eastern Time. Management will participate in one-on-one investor meetings during the conference. Investors interested in meeting with Ligand should contact their Barclays repres.

Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that effective March 1, 2024, Ligand's Human Capital Management and Compensation Committee approved the grant of a non-qualified stock option award to purchase 15,100 shares of its common stock to one non-executive employee. The grant date for the options was March 1, 2024. The award was granted under Ligand's 2022 Employment Inducement Plan, as amended (the “Inducement Plan”) as an employment inducem.

Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

News for Ligand Pharmaceuticals Stock (LGND)